Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an italian multicentric phase II study

被引：12

作者：

Piccaluga, Pier Paolo ^{[1
]}

Malagola, Michele ^{[2
]}

Rondoni, Michela ^{[1
]}

Arpinati, Mario ^{[1
]}

Paolini, Stefania ^{[1
]}

Candoni, Anna ^{[1
]}

Fanin, Renato ^{[3
]}

Messa, Emanuela ^{[4
]}

Pirrotta, Maria Teresa ^{[5
]}

Lauria, Francesco ^{[5
]}

Visani, Giuseppe ^{[6
]}

Alberti, Daniele

Rancati, Francesca

Vinaccia, Vincenza ^{[7
]}

Russo, Domenico

Saglio, Giuseppe ^{[4
]}

Baccarani, Michele ^{[1
]}

Martinelli, Giovanni ^{[1
]}

机构：

[1] Univ Bologna, S Orsola Malpighi Hosp, Inst Hematol & Med Oncol L & A Seragnoli, Via Massarenti 9, I-40138 Bologna, Italy

[2] Univ Brescia, Dept Hematol, Brescia, Italy

[3] Univ Udine, Dept Hematol, Udine, Italy

[4] Univ Torino, Dept Hematol, Orbassano, Turin, Italy

[5] Univ Siena, Dept Hematol, Siena, Italy

[6] Dept Hematol, Pesaro, Italy

[7] Novartis Pharmaceut, Origgio, Italy

来源：

HAEMATOLOGICA | 2007年 / 92卷 / 12期

关键词：

imatinib mesylate; acute myeloid leukemia; c-KIT; PDGFRB; targeted therapy;

D O I：

10.3324/haematol.11345

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We evaluated safety and efficacy of imatinib (600 mg) in 36 c-KIT+ acute myeloid leukemia patients not amenable to receive conventional chemotherapy. No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild.

引用

页码：1721 / 1722

页数：2